Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 6, 2026

Sezzle and Sea have been highlighted as Zacks Bull and Bear of the Day

View original at finance.yahoo.com
Sezzle and Sea have been highlighted as Zacks Bull and Bear of the Day For Immediate Release Chicago, IL – March 6, 2026 – Zacks Equity Research shares Sezzle SEZL as the Bull of the Day and Sea Ltd…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Projecting revenue growth of 25 to 30% year over year for FY26

    80% confidence

  • Management emphasized a focus on higher lifetime value subscribers and proprietary shopping features, positioning the company to sustain earnings quality into 2026

    80% confidence

  • Guiding to $170 million in adjusted net income, up 31% year over year on a per share basis for FY26

    80% confidence

  • Adjusted EBITDA at least flat year over year for 2026

    80% confidence

  • Sezzle is a Zack Rank #1 (Strong Buy)

    80% confidence

  • B. Riley Securities reiterated their 'Buy' rating on Sezzle

    80% confidence

  • Guiding to roughly 25% GMV growth at Shopee for 2026

    80% confidence

  • The Zacks Consensus Estimate for American Express' 2026 earnings is pegged at $17.50 per share, implying a 13.8% jump from the year-ago period

    80% confidence

  • Guiding to $4.70 in EPS versus $4.33 expected for FY26

    80% confidence

  • Sea Ltd. is a Zacks Rank #5 (Strong Sell)

    80% confidence

  • Garena is guiding to double digit bookings growth in 2026

    80% confidence

Data points we hold from this source

Visa Inc. · payments volume yoy growth8 percent

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com
Sezzle and Sea have been highlighted as Zacks Bull and Bear of the Day — Source | Via News | ViaNews EU